Literature DB >> 15761847

Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B.

Lilian Stärck1, Christian Scholz, Bernd Dörken, Peter T Daniel.   

Abstract

Costimulation is essential for induction of T lymphocyte proliferation and inhibition of activation-induced cell death. While signaling pathways activated following the ligation of the costimulatory molecule CD28 are well defined, less is known about the molecular events induced by alternative costimulators. CD137/4-1BB, a costimulatory member of the tumor necrosis factor receptor family, plays an important role during late primary T cell stimulation. Here, we demonstrate for the first time that inhibition of activation-induced cell death by exposure to the CD137/4-1BB ligand involves up-regulation of the anti-apoptotic protein c-FLIP(short). Inhibition of T cell death by 4-1BB ligation and up-regulation of c-FLIP(short) and Bcl-x(L) were abolished by blocking the phosphatidylinositol 3-kinase or the AKT/protein kinase B, which also mediate CD28-induced inhibition of activation-induced cell death. Our findings, therefore, demonstrate that costimulatory molecules, although belonging to different protein families and participating in distinct upstream signaling pathways, employ common downstream signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761847     DOI: 10.1002/eji.200425686

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

2.  The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.

Authors:  Xiaolong Tang; Qingguo Li; Yongqiang Zhu; Donghui Zheng; Jingjing Dai; Wenxuan Ni; Jia Wei; Yubao Xue; Ke Chen; Wei Hou; Chao Zhang; Xiaojun Feng; Yong Liang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

3.  Versatile strategy for controlling the specificity and activity of engineered T cells.

Authors:  Jennifer S Y Ma; Ji Young Kim; Stephanie A Kazane; Sei-Hyun Choi; Hwa Young Yun; Min Soo Kim; David T Rodgers; Holly M Pugh; Oded Singer; Sophie B Sun; Bryan R Fonslow; James N Kochenderfer; Timothy M Wright; Peter G Schultz; Travis S Young; Chan Hyuk Kim; Yu Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-12       Impact factor: 11.205

4.  Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma.

Authors:  Guoqiang Li; Xiaofeng Wu; Feng Zhang; Xiangcheng Li; Beicheng Sun; Yue Yu; Aihong Yin; Lei Deng; Jie Yin; Xuehao Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-19       Impact factor: 4.553

Review 5.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

6.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

7.  HIV-specific CD8+ T cells from elite controllers are primed for survival.

Authors:  Jiyu Yan; Steffanie Sabbaj; Anju Bansal; Nilesh Amatya; John J Shacka; Paul A Goepfert; Sonya L Heath
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

Review 8.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

Review 9.  Immune regulation and control of regulatory T cells by OX40 and 4-1BB.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-27       Impact factor: 7.638

10.  Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity.

Authors:  Stephanie J Ramos; Jeniffer B Hernandez; Martina Gatzka; Craig M Walsh
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.